Bancel letter showcases Moderna’s focus on mRNA vaccines

Moderna giving antiviral vaccines top billing in its sprawling mRNA pipeline reflects the growing consensus that the modality’s biggest near-term value lies in its potential to stoke immune responses.

With 21 candidates spanning six treatment paradigms and more than a dozen disease indications, Moderna’s pipeline breadth has been widely viewed as a key differentiating factor (see

Read the full 556 word article

User Sign In